ATL Technology Acquires Gyrus Medical LTD. Manufacturing Operations

Gyrus Medical is located in Cardiff, Wales, United Kingdom, is also a device outsourcer, and will increase both ATL’s global footprint and capabilities.

ATL Technology (ATL), a fast-growing provider of outsourced design, development and manufacturing services to the medical device market, today announced it has acquired manufacturing operations of Gyrus Medical Limited (Gyrus/GML) from Olympus Winter & Ibe GmbH (Olympus Surgical Technologies Europe).

Gyrus Medical is located in Cardiff, Wales, United Kingdom, is also a device outsourcer, and will increase both ATL’s global footprint and capabilities. In discussing this transaction, Joe Glover, CEO of ATL said, “This is a very strategic event for ATL. We look forward to incorporating Gyrus’ capabilities into ATL’s existing offerings and to expand our global footprint deeper onto the European continent.”

“We are also enthusiastic about welcoming the Gyrus team to ATL. Their significant engineering capabilities will enhance ATL’s existing resources, allowing ATL to continue its impressive growth rates”, said Glover.
Gyrus Executive Managing Director Simon Edwards said, “Over the past 30 years, Gyrus, much like ATL, has worked with medical device original equipment manufacturer (OEM) customers to develop and manufacture innovative solutions to improve patient care. We are looking forward to this strategic combination to continue and enhance this work for our OEM customers.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.